Access to anti-retroviral drugs, male in Kuwait

Kuwait: Access to anti-retroviral drugs, male was 71.0% in 2024. ▲ Rising

Latest (2024)
71.0%
Change on year
up 20.3%
World rank
69th
of 141 countries
All-time high
71.0%
in 2024
All-time low
32.0%
in 2015
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Kuwait, 2000–2024

0204060802000201220242000: 33 %2001: 35 %2002: 42 %2003: 41 %2004: 40 %2005: 44 %2006: 41 %2007: 38 %2008: 36 %2009: 34 %2010: 36 %2011: 35 %2012: 33 %2013: 36 %2014: 34 %2015: 32 %2016: 35 %2017: 35 %2018: 36 %2019: 42 %2020: 50 %2021: 49 %2022: 50 %2023: 59 %2024: 71 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Kuwait is 71.0%, measured in 2024. That is the highest value across all 25 years on record.

That represents a change of up 20.3% on the previous year and up 108.8% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Kuwait peaked at 71.0% in 2024 and was at its lowest, 32.0%, in 2015.

That places Kuwait 69th out of 141 countries with data for 2024, putting it in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, male in Kuwait, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Kuwait, 2000 to 2024.
Year % Change
2000 33.0%
2001 35.0% +6.1%
2002 42.0% +20.0%
2003 41.0% -2.4%
2004 40.0% -2.4%
2005 44.0% +10.0%
2006 41.0% -6.8%
2007 38.0% -7.3%
2008 36.0% -5.3%
2009 34.0% -5.6%
2010 36.0% +5.9%
2011 35.0% -2.8%
2012 33.0% -5.7%
2013 36.0% +9.1%
2014 34.0% -5.6%
2015 32.0% -5.9%
2016 35.0% +9.4%
2017 35.0% +0.0%
2018 36.0% +2.9%
2019 42.0% +16.7%
2020 50.0% +19.0%
2021 49.0% -2.0%
2022 50.0% +2.0%
2023 59.0% +18.0%
2024 71.0% +20.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 38.4% 33.0% 44.0% 10
2010s 35.4% 32.0% 42.0% 10
2020s 55.8% 49.0% 71.0% 5

Countries ranked near Kuwait

  1. 69 Nepal 71.0% compare
  2. 69 Sri Lanka 71.0% compare
  3. 72 Côte d'Ivoire 69.0% compare

See the full ranking of 160 places →

More gender data for Kuwait

All data for Kuwait →

Frequently asked questions

What is access to anti-retroviral drugs, male in Kuwait?
Access to anti-retroviral drugs, male in Kuwait was 71.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Kuwait?
The highest recorded value was 71.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Kuwait?
The lowest recorded value was 32.0% in 2015.
How does Kuwait rank for access to anti-retroviral drugs, male?
Kuwait ranks 69th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Kuwait?
Over the last ten years it is up 108.8%. The long-run trend across the full record is rising.
Where does this Kuwait data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Kuwait. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/kuwait/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/kuwait/">Access to anti-retroviral drugs, male in Kuwait</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.